NCT04539977View on ClinicalTrials.gov

PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2028

Conditions
Small-cell Lung Cancer
Interventions
DRUG

TQB2450

Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)

DRUG

TQB2450

Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER